BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker (SYK – Research Report) on December 28 and set a price target of $325.00. The company’s shares closed last Friday at $299.46.
According to TipRanks, Zimmerman is a 5-star analyst with an average return of 8.9% and a 47.46% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Vericel, and Stryker.
In addition to BTIG, Stryker also received a Buy from J.P. Morgan’s Robbie Marcus in a report issued on December 22. However, on the same day, Truist Financial maintained a Hold rating on Stryker (NYSE: SYK).
See Insiders’ Hot Stocks on TipRanks >>
SYK market cap is currently $113.8B and has a P/E ratio of 44.42.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stryker (SYK) Company Description:
Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.
Read More on SYK:
- 5 Top MedTech Stocks for 2024, According to Analysts from Baird
- Stryker price target raised to $320 from $300 at Truist
- Stryker announces intent to acquire SERF SAS
- Stryker announces intent to acquire SERF SAS, enhancing its global joint replacement leadership
- Stryker price target raised to $300 from $295 at Canaccord
